The history of microkhim as an implementation of the success formula
The philosophy of building a business in accordance with the leading trends in the development of the pharmaceutical market and modern standards of quality and management is at the heart of the achievements of Microkhim, a Ukrainian pharmaceutical company. At the same time, each period of its formation and development is marked by its own approaches and strategies.
1991
foundation of the company
1992
Release of low-tonnage API for nitro preparations
1995-1997
The technology of substance production from osorbide dinitrate is developed.
1998
Development and implementation of an installation for the production of NG in the form of an alcoholic solution and in a mixture with lactose
2000
Production of the first domestic preparations from osorbide dinitrate and nitroglycerin in spray form "Iso-Mick," "Nitro-Mick"
2002
Manufacture of tablet form "Iso-Mick" with a dosage of 5, 10 and 20 mg
2004
Release of Iso-Mick, an aqueous concentrate for infusions based on osorbide dinitrate of own production
2009
Production of injectable preparations based on API of own production under the trade names "Armadin" (EMGPS), "Trizipin" (TMGPD)
2011
Release of Dicor Long Modified Release
2012-2013
Microhim is the leader of the National Business Rating "Exporter of the Year" and "Importer of the Year"
2014
Start of cooperation with the Spanish company "INIBSA," the first project with a European partner
2015
«Nitromax» - sublingual tablets of 0.3 mg, 0.4 mg, 0.5 mg Nitropolicerine
2016
25th anniversary of successful work, staff of more than 200 people. There are 30 drugs in the portfolio. GMP certificate received
2017
Registered spray drug Strondex, which has no analogues in Ukraine, based on sildenafil
citrate2018
Registered the first domestic drug for the treatment of pulmonary arterial hypertension
2019
The company's own external service was launched. Release of ALITER products
2020
Growth of external service staff. Launch of Microchem ampoule shop. Development of drugs against COVID-19
2022
Until February 2022, the company's production functioned in the Lugansk region in Rubezhnoye. After a full-scale Russian invasion of Ukraine, production was forced to suspend its work.
In May 2022, the company changes its strategy and focuses on the team's competencies in the development and registration of medicines. Diversifies production - expands the list of sites for the production of medicines, entering into partnerships with major players in Ukraine and Europe.
2022-2023
2024